LeMaitre’s first quarter was marked by double-digit sales growth and significant margin expansion, yet the market responded negatively, reflecting concerns over certain operational trends. Management credited the quarter’s results to continued strength in core product lines—especially Artegraft, which saw exceptional international growth—and disciplined pricing strategies. CEO George LeMaitre noted, “Worldwide Artegraft sales grew 36% in Q1,” while also acknowledging product and geographic expansion as central to recent performance. Looking ahead, LeMaitre’s guidance is built on continued international rollout of Artegraft, further pricing initiatives, and operational investments to support expansion. Management highlighted upcoming launches in Canada and other regions, new product variants, and ongoing salesforce growth as key contributors to expected growth. CFO Dorian LeBlanc stated, “We are increasing our annual guidance for gross margin to 72.3%,” emphasizing the company’s focus on margin improvement and direct-to-hospital sales execution.
Is now the time to buy LMAT? Find out in our full research report (it’s free for active Edge members).
LeMaitre (LMAT) Q1 CY2026 Highlights:
- Revenue: $66.55 million vs analyst estimates of $66.72 million (11.2% year-on-year growth, in line)
- EPS (GAAP): $0.68 vs analyst estimates of $0.66 (3% beat)
- Adjusted EBITDA: $22.36 million vs analyst estimates of $20.19 million (33.6% margin, 10.8% beat)
- The company reconfirmed its revenue guidance for the full year of $280 million at the midpoint
- EPS (GAAP) guidance for the full year is $3.01 at the midpoint, beating analyst estimates by 3.5%
- Operating Margin: 26.7%, up from 21.1% in the same quarter last year
- Organic Revenue rose 10% year on year (miss)
- Market Capitalization: $2.32 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From LeMaitre’s Q1 Earnings Call
- Keith Hinton (Freedom Capital Markets) asked about the sustainability of high single-digit pricing increases, and CEO George LeMaitre detailed the differences in pricing flexibility and tender cycles between the U.S. and Europe.
- Hinton (Freedom Capital Markets) also inquired about patch performance, with CFO Dorian LeBlanc reporting XenoSure grew 5% and total patch category growth was 2.3% for the quarter.
- Michael Petusky (Barrington Research) asked if geopolitical events in the Middle East impacted operations, and CEO George LeMaitre noted only minor shipping delays and minimal cost impact so far.
- Petusky (Barrington Research) requested an M&A update, and President Dave Roberts confirmed active pursuit of targets but emphasized a disciplined approach and preference for organic growth.
- Michael Sarcone (Jefferies) sought details on the market opportunity for Quick Stick claims, with Roberts stating the addressable market is significant but that the regulatory process could take several years.
Catalysts in Upcoming Quarters
In upcoming quarters, the StockStory team will closely watch (1) the pace of Artegraft’s international rollout and the impact of new product variants, (2) progress on regulatory filings and direct market entries, particularly in Canada and Poland, and (3) sustained margin performance amid ongoing operational investments. Developments in M&A and further efficiency initiatives could also influence LeMaitre’s growth and profitability trajectory.
LeMaitre currently trades at $101.82, down from $112 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).
The Best Stocks for High-Quality Investors
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
